NCT06562920View on ClinicalTrials.gov

Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Interventions
DRUG

adebrelimab and chemotherapy

3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.

Trial Locations (1)

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER